Cargando…

F232. A PHASE 3 STUDY TO DETERMINE THE ANTIPSYCHOTIC EFFICACY AND SAFETY OF ALKS 3831 IN ADULT PATIENTS WITH ACUTE EXACERBATION OF SCHIZOPHRENIA

BACKGROUND: ALKS 3831, currently under development for the treatment of schizophrenia, is composed of a flexible dose of olanzapine (OLZ) and a fixed dose of 10 mg of samidorphan. In a Phase 2 study, ALKS 3831 mitigated OLZ-associated weight gain and exhibited antipsychotic efficacy similar to OLZ a...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDonnell, David, Potkin, Steven G, Simmons, Adam, Jiang, Ying, DiPetrillo, Lauren, Silverman, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888656/ http://dx.doi.org/10.1093/schbul/sby017.763

Ejemplares similares

S226. A STUDY COMPARING WEIGHT GAIN FROM ALKS 3831 TO OLANZAPINE IN EARLY-ILLNESS YOUNG ADULTS WITH SCHIZOPHRENIFORM, SCHIZOPHRENIA, OR BIPOLAR I DISORDER
por: Simmons, Adam, et al.
Publicado: (2018)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine‐Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study
por: Sun, Lei, et al.
Publicado: (2018)

An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder
por: Citrome, Leslie, et al.
Publicado: (2021)

Antipsychotic agents: efficacy and safety in schizophrenia
por: de Araújo, Arão Nogueira, et al.
Publicado: (2012)

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
por: Potkin, Steven, et al.
Publicado: (2013)

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research
por: Potkin, Steven G., et al.
Publicado: (2020)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022)

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Foussias, George, et al.
Publicado: (2018)

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
por: Correll, Christoph U, et al.
Publicado: (2022)

S232. ALPHA7 NICOTINIC RECEPTOR AGONISTS REVERSE THE HYPERDOPAMINERGIC STATE IN THE MAM MODEL OF SCHIZOPHRENIA
por: Neves, Gilda, et al.
Publicado: (2018)

T232. PREMORBID SOCIAL FUNTIONING AND AFFECTIVE SYMTPOMS ARE RELATED TO SUBJECTIVE OUTCOME AMONG OUTPATIENTS WITH SCHIZOPHRENIA
por: Hörtnagl, Christine, et al.
Publicado: (2020)

Health Tract, No. 232: Sordid
Publicado: (1865)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Messe in h-moll, BWV 232
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1984)

Mass in B minor, BWV 232
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1992)

Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder
por: Doane, Michael J., et al.
Publicado: (2022)

F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
por: Davis, Robert, et al.
Publicado: (2018)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Comparative effectiveness of antipsychotic drugs in schizophrenia
por: Stroup, T. Scott, et al.
Publicado: (2000)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
por: Wu, Haishan, et al.
Publicado: (2013)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

The beta-decay scheme of /sup 232/Fr and the K=0 ground-state band in /sup 232/Ra
por: Peräjärvi, K, et al.
Publicado: (2004)

PMH26 Early Impact of COVID-19 Pandemic on Antipsychotic Medication Use Among Patients with Schizophrenia
por: Pesa, J., et al.
Publicado: (2021)

Fission Fragment Angular Distribution of 232Th(n,f) at the CERN n_TOF Facility
por: Tarrío, D, et al.
Publicado: (2014)

F35. PRESCRIPTION PATTERN OF ANTIPSYCHOTICS FOR CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA IN KOREA BASED ON NATIONWIDE DATA
por: Park, Kee Jeong, et al.
Publicado: (2018)

F161. BRAIN VOLUME CHANGE IN PATIENTS WITH SCHIZOPHRENIA AND ITS RELATION WITH ANTIPSYCHOTIC DRUG USE
por: Kiras, Fatma, et al.
Publicado: (2018)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

LHC MD 232: Longitudinal Impedance Evaluation
por: Esteban Muller, Juan, et al.
Publicado: (2017)

Fission of muonic $^232$Th and $^{238}U$
por: Ganzorig, D, et al.
Publicado: (1978)

Measurement of the fission fragment angular distribution for 232Th(n,f) at the CERN n-TOF facility
por: Tarrío, D, et al.
Publicado: (2012)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Developments in antipsychotic therapy with regard to hypotheses for schizophrenia
por: Ackenheil, Manfred, et al.
Publicado: (2002)

Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
por: Marcus, Steven C., et al.
Publicado: (2008)

Neuroanatomical correlates of psychopathology in antipsychotic-naïve schizophrenia
por: Venkatasubramanian, Ganesan
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_1pf17hpp6n3u9ne3kf8jodfsbg